Homocyst(e)ine and heart disease: pathophysiology of extracellular matrix
- PMID: 10225475
- DOI: 10.3109/10641969909068660
Homocyst(e)ine and heart disease: pathophysiology of extracellular matrix
Abstract
Occlusive coronary artery disease is an important factor of cardiovascular morbidity and mortality. The rupture of the thin fibrous cap of the atheroma may be one of the causes of acute coronary syndrome, however, the mechanism of formation of fibrous plaque are poorly understood. Elevation of plasma homocysteine, hyperhomocystinemia, H(e), has emerged as an independent risk factor for hypertension and fibrotic heart disease. The extracellular matrix (ECM) components, particularly fibrillar collagen, are elevated in the atherosclerotic lesions and are the essential integral element in holding the oxidized low density lipoproteins (LDL), homocystine, macrophage and foam cells in milieu, constituting the primary atherosclerotic and secondary restenotic lesions. In vivo and in vitro physiological, morphological, cellular, biochemical and molecular experiments have suggested the role of tissue homocystine in cardiovascular fibrosis and adverse ECM remodeling following H(e). The tissue homocystine induces cardiovascular fibrosis and may lead to heart failure via the redox-receptor pathway. The underlying cause and mechanism of cardiovascular fibrosis associated with arteriosclerosis, atherosclerosis, hypertension and coronary heart disease, involve changes in the levels of tissue redox state.
Similar articles
-
Reduction-oxidation (Redox) and vascular tissue level of homocyst(e)ine in human coronary atherosclerotic lesions and role in extracellular matrix remodeling and vascular tone.Mol Cell Biochem. 1998 Apr;181(1-2):107-16. doi: 10.1023/a:1006882014593. Mol Cell Biochem. 1998. PMID: 9562247
-
Homocysteine redox receptor and regulation of extracellular matrix components in vascular cells.Am J Physiol. 1998 Feb;274(2):C396-405. doi: 10.1152/ajpcell.1998.274.2.C396. Am J Physiol. 1998. PMID: 9486129
-
The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease.J Vasc Surg. 1991 Jan;13(1):128-36. doi: 10.1067/mva.1991.24913. J Vasc Surg. 1991. PMID: 1987384
-
Patients with atherosclerotic vascular disease: how low should plasma homocyst(e)ine levels go?Am J Cardiovasc Drugs. 2001;1(2):85-9. doi: 10.2165/00129784-200101020-00002. Am J Cardiovasc Drugs. 2001. PMID: 14728038 Review.
-
[Homocysteine, endothelial dysfunction and cardiovascular risk: pathomechanisms and therapeutic options].Z Kardiol. 2001 Jan;90(1):1-11. doi: 10.1007/s003920170206. Z Kardiol. 2001. PMID: 11220081 Review. German.
Cited by
-
Mechanism of Blood-Heart-Barrier Leakage: Implications for COVID-19 Induced Cardiovascular Injury.Int J Mol Sci. 2021 Dec 17;22(24):13546. doi: 10.3390/ijms222413546. Int J Mol Sci. 2021. PMID: 34948342 Free PMC article.
-
Ablation of MMP9 gene ameliorates paracellular permeability and fibrinogen-amyloid beta complex formation during hyperhomocysteinemia.J Cereb Blood Flow Metab. 2014 Sep;34(9):1472-82. doi: 10.1038/jcbfm.2014.102. Epub 2014 May 28. J Cereb Blood Flow Metab. 2014. PMID: 24865997 Free PMC article.
-
Role of nitric oxide in matrix remodeling in diabetes and heart failure.Heart Fail Rev. 2003 Jan;8(1):23-8. doi: 10.1023/a:1022138803293. Heart Fail Rev. 2003. PMID: 12652156 Review.
-
MicroRNAs are involved in homocysteine-induced cardiac remodeling.Cell Biochem Biophys. 2009;55(3):153-62. doi: 10.1007/s12013-009-9063-6. Epub 2009 Aug 11. Cell Biochem Biophys. 2009. PMID: 19669742 Free PMC article.
-
Epigenetics, 1-Carbon Metabolism, and Homocysteine During Dysbiosis.Front Physiol. 2021 Feb 23;11:617953. doi: 10.3389/fphys.2020.617953. eCollection 2020. Front Physiol. 2021. PMID: 33708132 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
